Fintel reports that on January 10, 2025, BTIG initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy recommendation.

Energy & Infrastructure Analyst Lewis and Fixed Income Strategist Malley discuss bitcoin mining trends and themes across the capital ...

BTIG analyst Justin Zelin lowered the firm’s price target on Jasper Therapeutics (JSPR) to $64 from $90 and keeps a Buy rating on the shares ...

Fintel reports that on January 8, 2025, BTIG downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Neutral.

The S&P 500's rally of 1.8% over just the last two sessions is nice, "but not a game changer yet," according to BTIG's technical guru, Jonathan Krinsky. The chart he provides, below, shows the stock ...

BTIG's Krinsky noted that while equity markets in the first half of 2024 were fueled mostly by the surge in mega-cap names ...

According to a BTIG strategist, the rally in the index was rejected from the previous support trendline and even though there are still four days left for the Santa Claus rally to deliver gains, there ...

Apple (AAPL) shares are up about 8% over the past month. But BTIG chief market technician Jonathan Krinsky is warning ...

Palo Alto Networks (NASDAQ: PANW) investors just cannot catch a break. Over the past three days, this cybersecurity stock has been downgraded by three separate investment bank analysts, beginning with ...

BTIG analyst Gray Powell keeps a Buy rating and $30 price target on SentinelOne (S) but names the stock the firm’s Top Pick in Security & Infrastructure Software for 2025. The stock is ...

As of December 3, 2024, the average one-year price target for Avalo Therapeutics is $35.70/share. The forecasts range from a low of $35.35 to a high of $36.75. The average price target represents ...